


Frame S, Saladino C, Hogben M, Armour S, Zheleva D, Green S, and Blake D. Sapacitabine efficacy is enhanced in homologous recombination defective tumours. In: National Cancer


**Frame S**, Armour S, Zheleva DI, Green SR, and Blake DG. DNA repair defects enhance tumor cell sensitivity to sapacitabine. **In: Proceedings of the 103rd Annual Meeting of the American**


Frame S., MacKay R.H., Hogben M., Connolly C., Anderson S., Fleming I.N., Davis S., Blake D., Green S. Exploiting the unique mechanism of action of sapacitabine (CYC682) to obtain synergy with other therapeutic agents for clinical use in Acute Myeloid Leukemia, 14th Congress
of the European Hematology Association (EHA), June 4-7, 2009, Berlin, Germany, Abstract 0761.

**Garcia-Manero G., Luger S., Venugopal P., Maness L., Wetzler M., Coutre S., Stock W., Borthakur1 G., Chiao J.H., & Kantarjian H.** A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS, *J Clin Oncol* 27:15s, 2009 (suppl; abstr 7021).


**Fleming I.N., Choudhary, A. K, Mackay, R. H, Green, S.R & Davis, S.** The nucleoside analogue sapacitabine (CYC682) synergises with histone deacetylase inhibitors in multiple tumour types. Poster. *20th EORTC-NCI-AACR Meeting. EJC Supplement, 2008 6 (12);150.*


McClue, S., and Stuart, I., Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 2008 36:561.


Chassagnole C; Jackson RC; Hussain N; Bashir L; Derow C; Savin J; Fell DA. Using a mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development. BioSystems (2006); 83: 91-97.


McInnes, C.; Mezna M.; Fischer P. M.; Progress in the Discovery of Polo-like Kinase Inhibitors. Current topics in Medicinal Chemistry 2005: 5:181.


Kontopidis, G.: Wu S.-Y., Zheleva D., Taylor P., McInnes C., Lane D.P., Fischer P.M., Walkinshaw M.D. Structural and biochemical studies of human proliferating cell nuclear antigen


McInnes C., Second Annual Protein Kinases Conference: Addressing the challenges across the Kinome; Kinase drug discovery and disease biology; *IDrugs* 2003: 6(12):1135.

McInnes C., Second Annual Protein Kinases Conference: Addressing the challenges across the Kinome; Clinical Update, new therapies and new technologies; *IDrugs* 2003: 6(12):1138.


of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine.


**Raynaud F.I.,** Nutley B.P., Goddard P.M., Fischer P., McClue S., Lane D., Workman P. Cassette dosing is a valid approach to evaluate the pharmacokinetics of trisubstituted purines such as Olomoucine, Roscovitine and Bohemine. *Br. J. Cancer Res.* 2000:83(Suppl. 1): 68.


